Imeglimin is a promising antidiabetic drug that is currently in clinical trials. During the drug development process, impurities can form due to various factors such as synthesis, storage, and handling. These impurities can affect the efficacy, safety, and stability of the drug. Therefore, the identification, characterization, and control of Imeglimin impurities are crucial for ensuring the quality and efficacy of the drug.